The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer

(2013) Luigi Marchionni et al.   ANNALS OF INTERNAL MEDICINE

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

P5-14-26: Results from a Prospective Clinical Study on the Impact of Oncotype DX on Adjuvant Treatment Decision Making in a Cohort of 142 UK Patients.

(2012) S Holt et al.   CANCER RESEARCH

P2-12-26: Impact of the Recurrence Score on Adjuvant Decision-Making in ER-Positive Early Breast Cancer – Results of a Large Prospective Multicentre Decision Impact Study in Node Negative and Node Positive Disease.

(2012) M Rezai et al.   CANCER RESEARCH

Factors Associated With Receipt of Breast Cancer Adjuvant Chemotherapy in a Diverse Population-Based Sample

(2012) Jennifer J. Griggs et al.   JOURNAL OF CLINICAL ONCOLOGY

A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies

(2012) Johannes R Kratz et al.   LANCET

Genomic Predictors of Outcome and Treatment Response in Breast Cancer

(2012) Lara Dunn et al.   Molecular Diagnosis & Therapy

The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy

(2011) D. B. Geffen et al.   ANNALS OF ONCOLOGY

Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Positive Breast Cancer

(2011) Jessica F. Partin et al.   ANNALS OF SURGICAL ONCOLOGY

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20

(2011) Gong Tang et al.   BREAST CANCER RESEARCH AND TREATMENT

21-Gene recurrence scores

(2011) Mary Jo Lund et al.   CANCER

Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer

(2011) Richard G. Gray et al.   JOURNAL OF CLINICAL ONCOLOGY

The Effect of Oncotype DX Recurrence Score on Treatment Recommendations for Patients with Estrogen Receptor-Positive Early Stage Breast Cancer and Correlation with Estimation of Recurrence Risk by Breast Cancer Specialists

(2011) J. E. Joh et al.   ONCOLOGIST

The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort

(2010) Foluso O. Ademuyiwa et al.   BREAST CANCER RESEARCH AND TREATMENT

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers

(2010) Catherine M. Kelly et al.   CANCER

Women's experiences with genomic testing for breast cancer recurrence risk

(2010) Janice P. Tzeng et al.   CANCER

Experience with Use of the Oncotype DX Gene Assay Test in a Multicenter Community-Based Healthcare System.

(2010) X. Gregg et al.   CANCER RESEARCH

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

(2010) Eleftherios P. Mamounas et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection

(2010) Shelly S. Lo et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast cancer assessment tools and optimizing adjuvant therapy

(2010) Catherine Oakman et al.   Nature Reviews Clinical Oncology

Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization

(2010) Shmuel H. Klang et al.   VALUE IN HEALTH

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays

(2009) Kathy S. Albain et al.   BREAST

Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

(2009)   GENETICS IN MEDICINE

The influence of a Gene expression profile on breast cancer decisions

(2009) Leonard R. Henry et al.   JOURNAL OF SURGICAL ONCOLOGY

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

(2008) Juhi Asad et al.   AMERICAN JOURNAL OF SURGERY

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen

(2008) Marleen Kok et al.   BREAST CANCER RESEARCH AND TREATMENT

Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials

(2008) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients

(2007) Ido Wolf et al.   CANCER